Rapid Norovirus Assay Approved for Diagnostic Use in the United States
By LabMedica International staff writers Posted on 15 Dec 2014 |
A dedicated laboratory-in-a-cartridge assay that enables the rapid diagnosis of norovirus infection has been approved for use in the United States.
The Food and Drug Administration (FDA) approved the single use Xpert Norovirus assay, which runs on Cepheid's (Sunnyvale, CA, USA) GeneXpert System, one of the world's leading molecular diagnostic platforms with more than 7,000 systems installed to date. The Xpert Norovirus assay is a qualitative in vitro diagnostic test for rapid identification and differentiation of noroviruses genogroup I (GI) and genogroup II (GII).
Cepheid's GeneXpert System is a closed, self-contained, fully-integrated, and automated platform that combines on-board sample preparation with real-time PCR (polymerase chain reaction) amplification and detection functions for fully integrated and automated nucleic acid analysis. The system is designed to purify, concentrate, detect, and identify targeted nucleic acid sequences thereby delivering answers directly from unprocessed samples.
"Norovirus exposure is an unfortunate fact of life. The associated illness can spread quickly in the hospital setting and be very serious, especially in young children and older adults," said John Bishop, CEO of Cepheid. "To actively manage the infection, clinicians have previously been forced to choose between accuracy and time-to-result when selecting a testing method — now no compromise is required as Xpert Norovirus delivers both."
"Xpert Norovirus enables on-demand molecular detection and differentiation of the GI and GII Norovirus genogroups, which together account for the vast majority of human infections," said Dr. David H. Persing, CMO and CTO at Cepheid. "Norovirus outbreaks require immediate implementation of targeted infection control procedures, and this new test gives clinicians accurate results in as little as one hour."
Related Links:
Cepheid
The Food and Drug Administration (FDA) approved the single use Xpert Norovirus assay, which runs on Cepheid's (Sunnyvale, CA, USA) GeneXpert System, one of the world's leading molecular diagnostic platforms with more than 7,000 systems installed to date. The Xpert Norovirus assay is a qualitative in vitro diagnostic test for rapid identification and differentiation of noroviruses genogroup I (GI) and genogroup II (GII).
Cepheid's GeneXpert System is a closed, self-contained, fully-integrated, and automated platform that combines on-board sample preparation with real-time PCR (polymerase chain reaction) amplification and detection functions for fully integrated and automated nucleic acid analysis. The system is designed to purify, concentrate, detect, and identify targeted nucleic acid sequences thereby delivering answers directly from unprocessed samples.
"Norovirus exposure is an unfortunate fact of life. The associated illness can spread quickly in the hospital setting and be very serious, especially in young children and older adults," said John Bishop, CEO of Cepheid. "To actively manage the infection, clinicians have previously been forced to choose between accuracy and time-to-result when selecting a testing method — now no compromise is required as Xpert Norovirus delivers both."
"Xpert Norovirus enables on-demand molecular detection and differentiation of the GI and GII Norovirus genogroups, which together account for the vast majority of human infections," said Dr. David H. Persing, CMO and CTO at Cepheid. "Norovirus outbreaks require immediate implementation of targeted infection control procedures, and this new test gives clinicians accurate results in as little as one hour."
Related Links:
Cepheid
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Technology News
- New Diagnostic System Achieves PCR Testing Accuracy
- DNA Biosensor Enables Early Diagnosis of Cervical Cancer
- Self-Heating Microfluidic Devices Can Detect Diseases in Tiny Blood or Fluid Samples
- Breakthrough in Diagnostic Technology Could Make On-The-Spot Testing Widely Accessible
- First of Its Kind Technology Detects Glucose in Human Saliva
- Electrochemical Device Identifies People at Higher Risk for Osteoporosis Using Single Blood Drop
- Novel Noninvasive Test Detects Malaria Infection without Blood Sample
- Portable Optofluidic Sensing Devices Could Simultaneously Perform Variety of Medical Tests
- Point-of-Care Software Solution Helps Manage Disparate POCT Scenarios across Patient Testing Locations
- Electronic Biosensor Detects Biomarkers in Whole Blood Samples without Addition of Reagents
- Breakthrough Test Detects Biological Markers Related to Wider Variety of Cancers
- Rapid POC Sensing Kit to Determine Gut Health from Blood Serum and Stool Samples
- Device Converts Smartphone into Fluorescence Microscope for Just USD 50
- Wi-Fi Enabled Handheld Tube Reader Designed for Easy Portability